Back to search

Peptide record

TPDB22271

Antibacterial Hemolysis Toxicity standard
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB22271
Antibacterial Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
Peptipedia PD_Hemolysis
standard
No
A 8-aa standard natural multi-activity (Antibacterial, Hemolysis, and Toxicity) peptide sequence curated from Peptipedia and PD_Hemolysis, with an available 3D structural model.
Sequence
KRIWQRIK
Physicochemical Analysis
C52H90N18O10
ANDCEGHLMFPSTYV
RIK
1127.40
12.42
4
0
3
+4
1.71
-1.525
97.50
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
487.85
1
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
1
Q
0
G
0
H
2
I
0
L
2
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 2 L: 0 K: 2 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
8
C52H90N18O10
1127.40
12.42
+4
1.71
-1.525
Evidence Records 9 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
<25 µM
Hemolytic Cytotoxic
50% Hemolysis | <25 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
35 µM
Hemolytic Cytotoxic
50% Hemolysis | 35 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 3 Activity

Activity

50% Hemolysis
Toxicity
300 µM
Hemolytic Cytotoxic
50% Hemolysis | 300 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 4 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 5 Activity

Activity

40% Cytotoxicity
Toxicity
100 µM
Cytotoxic
40% Cytotoxicity | 100 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 6 Activity

Activity

50% Hemolysis
Toxicity
>200 µM
Hemolytic Cytotoxic
50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short and Robust Anti-Infective Lipopeptides Engineered Based on the Minimal Antimicrobial Peptide KR12 of Human LL-37. | ACS Infect Dis | 2021
Evidence 7 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Screening Sensitivity Enabled the Identification of an Ultrashort Peptide KR-8 for Engineering of LL-37mini to Combat Drug-Resistant Pathogens. | ACS Infect Dis | 2023
Evidence 8 Activity

Activity

50% Cell death
Toxicity
>100 µM
Cytotoxic
50% Cell death | >100 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
Enhanced Antimicrobial Screening Sensitivity Enabled the Identification of an Ultrashort Peptide KR-8 for Engineering of LL-37mini to Combat Drug-Resistant Pathogens. | ACS Infect Dis | 2023
Evidence 9 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis